Safety and Efficacy of Anti-SARS-CoV-2 Equine Antibody F(ab')2 Fragments (INOSARS) for Adult Patients With Mild COVID-19

Key Inclusion criteria * Outpatient with a RT-qPCR confirmation of SARS-CoV-2 infection * Body Mass Index (BMI) at screening of 18.0 - 34.9 kg/m\^2 * Presence of at least one symptom consistent with COVID-19 * Mild illness as defined by no requirement of supplementary oxygen or hospitalization criteria are met Key Exclusion criteria * Presence of a risk factor for disease progression documented for COVID-19 such as: uncontrolled diabetes, uncontrolled hypertension, cardiovascular disease, pulmonary disease, COPD, asthma, active cancer, immunosuppression, hypercoagulable states, CKD currently under dialysis * Documented allergy to equine serum proteins * Previous hospitalization due to COVID-19 * Supplementary oxygen, invasive ventilation, or mechanical circulatory support requirements * Having received convalescent plasma or intravenous immunoglobulins for the treatment of COVID-19 * Previous vaccination or plans to get vaccinated for COVID-19 * In the opinion of investigator, other health conditions that suppose an increased risk of progression of disease NOTE: Other inclusion/exclusion criteria apply